logo-loader
viewTissue Regenix Group PLC

Tissue Regenix PLC granted US clearance for hernia implant

It is the first time an implant using Tissue’s cell washing technology has been approved by the US Food and Drug Administration.

SportInjury.jpg
The 'groin strain' may not be so much of a problem in future

Regenerative medtech Tissue Regenix (LON:TRX) has been granted US regulatory clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue.

It is the first time an implant using Tissue’s cell washing technology has been approved by the US Food and Drug Administration.

The clearance clears SurgiPure XD for a commercial launch in the US later this year.

Antony Odell, Tissue Regenix’s chief executive, said he was delighted with this first clearance for a dCELL application.

“The US is a key market for us and we have proven that we can successfully commercialise product here already with DermaPure [a skin graft for open wounds].

SurgiPure XD will be used alongside dCELL to repair hernias or body wall defects by bolstering areas where soft tissue has been weakened.

The hernia market is worth US$2-3bn  with the US alone worth US$1bn. Biologic treatments account for around US$300mln.

 “Tissue Regenix dCELL applications are quickly gaining clinical validation and demand on an international scale, through both the Wound Care and Cardiac sectors, a testament to the strength of our dCELL technology platform,” said Odell.

Quick facts: Tissue Regenix Group PLC

Price: 1.029 GBX

AIM:TRX
Market: AIM
Market Cap: £12.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Tissue Regenix to boost production capacity as its sees...

Tissue Regenix Group PLC's (LON:TRX) Gareth Jones tells Proactive London's Andrew Scott they're focused on initiatives to increase capacity and alleviate supply constraints as they continue to see strong demand for its products. Sales rose £500,000 to £6.1mln during the six months ended...

on 11/9/19

2 min read